The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SPRINT
- 04 Jun 2019 Results (n=5) assessing efficacy of pembrolizumab in patients with locally advanced non-small cell lung cancer patients, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 05 Sep 2018 Status changed from not yet recruiting to recruiting.
- 17 May 2018 New trial record